Cantourage and CannFX – New Zealand’s leading cannabis distributor – have partnered to expand offerings available on the Cantourage platform for wholesalers and pharmacists.
CannFX has signed deals with several growers in New Zealand to bring high-quality, non-irradiated cannabis flower to the global market.
CannFX’s first THC strain, “Wappa”, is now available and the product is expected to be available in additional European markets, including the UK, in early 2023.
Read more: Cantourage launches in scale segment of Frankfurt Stock Exchange
CEO of Cantourage, Philip Schetter, commented: “We are very excited about our new partnership with CannFX.
“With CannFX’s products now available through our platform, we are advancing our goal of bringing medicinal cannabis from around the world to Europe and thus offer patients more treatment options.”
CannFX was founded in 2019 with the vision of bringing medicinal cannabis grown in New Zealand to patients around the world.
The company has signed deals with the best growers in New Zealand to supply the global markets with high quality dried cannabis flower.
CEO of CannFX, Bastiaan Kramer, added: “Giving patients access to our products in additional markets is a top priority for us.
‘This is an expansion of our global footprint while also sending a strong signal to the New Zealand cannabis industry.
“The EU and UK are important and fast-growing markets and we look forward to making a contribution to meet the needs of the growing number of patients there.”
The development follows Cantourage Group SE’s listing of its shares on the Frankfurt Stock Exchange under the ticker symbol HIGH, WKN A3DSV0 and ISIN DE000A3DSV01.
